{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:36:41Z","timestamp":1707525401177},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,27]]},"DOI":"10.7759\/cureus.47821","type":"journal-article","created":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T17:07:46Z","timestamp":1698426466000},"source":"Crossref","is-referenced-by-count":0,"title":["Emerging Diagnostics and Therapeutics for Non-alcoholic Fatty Liver Disease"],"prefix":"10.7759","author":[{"given":"Jake","family":"Darbhanga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiarra","family":"Krulikowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne I","family":"Riskin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0173499","article-title":"Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States","volume":"12","author":"Le MH","year":"2017","unstructured":"Le MH, Devaki P, Ha NB, Jun DW, Te HS, Cheung RC, Nguyen MH. Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States. PLoS One. 2017, 12:e0173499. 10.1371\/journal.pone.0173499","journal-title":"PLoS One"},{"key":"ref2","article-title":"Fibroscan (transient elastography) for the measurement of liver fibrosis","volume":"8","author":"Afdhal NH","year":"2012","unstructured":"Afdhal NH. Fibroscan (transient elastography) for the measurement of liver fibrosis. Gastroenterol Hepatol (N Y). 2012, 8:605-7.","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000001365","article-title":"The clinical usefulness of elastography in the evaluation of nonalcoholic fatty liver disease patients: a biopsy-controlled study","volume":"31","author":"Darweesh SK","year":"2019","unstructured":"Darweesh SK, Omar H, Medhat E, Abd-Al Aziz RA, Ayman H, Saad Y, Yosry A. The clinical usefulness of elastography in the evaluation of nonalcoholic fatty liver disease patients: a biopsy-controlled study. Eur J Gastroenterol Hepatol. 2019, 31:1010-6. 10.1097\/MEG.0000000000001365","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-019-01635-0","article-title":"Accuracy of liver stiffness measurement and controlled attenuation parameter using FibroScan(\u00ae) M\/XL probes to diagnose liver fibrosis and steatosis in patients with nonalcoholic fatty liver disease: a multicenter prospective study","volume":"55","author":"Oeda S","year":"2020","unstructured":"Oeda S, Takahashi H, Imajo K, et al.. Accuracy of liver stiffness measurement and controlled attenuation parameter using FibroScan(\u00ae) M\/XL probes to diagnose liver fibrosis and steatosis in patients with nonalcoholic fatty liver disease: a multicenter prospective study. J Gastroenterol. 2020, 55:428-40. 10.1007\/s00535-019-01635-0","journal-title":"J Gastroenterol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s12877-021-02239-1","article-title":"Associations between nut intake, cognitive function and non-alcoholic fatty liver disease (NAFLD) in older adults in the United States: NHANES 2011-14","volume":"21","author":"Tan SY","year":"2021","unstructured":"Tan SY, Georgousopoulou EN, Cardoso BR, Daly RM, George ES. Associations between nut intake, cognitive function and non-alcoholic fatty liver disease (NAFLD) in older adults in the United States: NHANES 2011-14. BMC Geriatr. 2021, 21:313. 10.1186\/s12877-021-02239-1","journal-title":"BMC Geriatr"},{"key":"ref6","article-title":"Screening for nonalcoholic fatty liver disease in the primary care clinic","volume":"15","author":"Pandyarajan V","year":"2019","unstructured":"Pandyarajan V, Gish RG, Alkhouri N, Noureddin M. Screening for nonalcoholic fatty liver disease in the primary care clinic. Gastroenterol Hepatol (N Y). 2019, 15:357-65.","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/ptr.6073","article-title":"Efficacy of artichoke leaf extract in non-alcoholic fatty liver disease: a pilot double-blind randomized controlled trial","volume":"32","author":"Panahi Y","year":"2018","unstructured":"Panahi Y, Kianpour P, Mohtashami R, et al.. Efficacy of artichoke leaf extract in non-alcoholic fatty liver disease: a pilot double-blind randomized controlled trial. Phytother Res. 2018, 32:1382-7. 10.1002\/ptr.6073","journal-title":"Phytother Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000001369","article-title":"Treatment options for nonalcoholic fatty liver disease: a double-blinded randomized placebo-controlled trial","volume":"31","author":"Anushiravani A","year":"2019","unstructured":"Anushiravani A, Haddadi N, Pourfarmanbar M, Mohammadkarimi V. Treatment options for nonalcoholic fatty liver disease: a double-blinded randomized placebo-controlled trial. Eur J Gastroenterol Hepatol. 2019, 31:613-7. 10.1097\/MEG.0000000000001369","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/ptr.6406","article-title":"Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: a randomized, placebo-controlled, double-blind clinical trial","volume":"33","author":"Cheraghpour M","year":"2019","unstructured":"Cheraghpour M, Imani H, Ommi S, et al.. Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: a randomized, placebo-controlled, double-blind clinical trial. Phytother Res. 2019, 33:2118-25. 10.1002\/ptr.6406","journal-title":"Phytother Res"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000000981","article-title":"Comparison of fenofibrate and pioglitazone effects on patients with nonalcoholic fatty liver disease","volume":"29","author":"Yaghoubi M","year":"2017","unstructured":"Yaghoubi M, Jafari S, Sajedi B, Gohari S, Akbarieh S, Heydari AH, Jameshoorani M. Comparison of fenofibrate and pioglitazone effects on patients with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2017, 29:1385-8. 10.1097\/MEG.0000000000000981","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0151829","article-title":"Bile acids and dysbiosis in non-alcoholic fatty liver disease","volume":"11","author":"Mouzaki M","year":"2016","unstructured":"Mouzaki M, Wang AY, Bandsma R, et al.. Bile acids and dysbiosis in non-alcoholic fatty liver disease. PLoS One. 2016, 11:e0151829. 10.1371\/journal.pone.0151829","journal-title":"PLoS One"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/jn\/nxy088","article-title":"Daily consumption of synbiotic yogurt decreases liver steatosis in patients with nonalcoholic fatty liver disease: a randomized controlled clinical trial","volume":"148","author":"Bakhshimoghaddam F","year":"2018","unstructured":"Bakhshimoghaddam F, Shateri K, Sina M, Hashemian M, Alizadeh M. Daily consumption of synbiotic yogurt decreases liver steatosis in patients with nonalcoholic fatty liver disease: a randomized controlled clinical trial. J Nutr. 2018, 148:1276-84. 10.1093\/jn\/nxy088","journal-title":"J Nutr"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/7095684","article-title":"Alcohol induces more severe fatty liver disease by influencing cholesterol metabolism","volume":"2019","author":"Li B","year":"2019","unstructured":"Li B, Lei SS, Su J, et al.. Alcohol induces more severe fatty liver disease by influencing cholesterol metabolism. Evid Based Complement Alternat Med. 2019, 2019:7095684. 10.1155\/2019\/7095684","journal-title":"Evid Based Complement Alternat Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/170824-emerging-diagnostics-and-therapeutics-for-non-alcoholic-fatty-liver-disease","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:07:45Z","timestamp":1707509265000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/170824-emerging-diagnostics-and-therapeutics-for-non-alcoholic-fatty-liver-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,27]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.47821","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10,27]]}}}